Achiko AG expected to have AptameX in widespread commercial availability in third quarter of 2022.
1st Jan change | Capi. | |
---|---|---|
+1.54% | 176B | |
+17.28% | 39.71B | |
+0.87% | 38.61B | |
+39.56% | 15.78B | |
-26.70% | 10.72B | |
+34.51% | 9.9B | |
-20.82% | 8.98B | |
+61.44% | 6.94B | |
-6.82% | 5.17B |
Achiko AG expected to have AptameX in widespread commercial availability in third quarter of 2022.
1st Jan change | Capi. | |
---|---|---|
+1.54% | 176B | |
+17.28% | 39.71B | |
+0.87% | 38.61B | |
+39.56% | 15.78B | |
-26.70% | 10.72B | |
+34.51% | 9.9B | |
-20.82% | 8.98B | |
+61.44% | 6.94B | |
-6.82% | 5.17B |